Accueil   Diary - News   All news SIGNIA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF KEY LICENSING AND PHASE 2 CLINICAL TRIAL MILESTONES

SIGNIA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF KEY LICENSING AND PHASE 2 CLINICAL TRIAL MILESTONES

 

 

 

LYON, FRANCE (January 21, 2018) – Signia Therapeutics is an emerging spin-off company of VirPath laboratory/Université Claude Bernard Lyon (UCBL), that proposes an innovative and versatile platform for antiviral drugs discovery and repositioning or recycling, based on a global targeting of the host cell instead of specific viral determinants.

 

The research strategy is based on the direct exploitation of clinical samples from infected patients and the characterization by NGS of relevant in vivo transcriptomic signatures of infections, in an innovative bedside-to-bench and bench-to-bedside approach. The Company’s capabilities are well adapted to study the pathogenesis of respiratory acute infections and provides a breakthrough methodology for the identification and validation of effective and broad-spectrum antivirals.ctre.

 

 

Licensing and collaboration agreements


Signia Therapeutics has completed a major licence agreement with the Université Claude Bernard of Lyon (UCBL) and the Université Laval of Québec to obtain full exclusive international rights for three patents comprising eight repurposed marketed drugs as new antivirals against influenza viruses or the Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV) (WO2016146836; PCT/EP2017/058009; PCT/FR2017/052889). These new antivirals were identified and validated through a proprietary discovery platform, and are now part of the Company’s pipeline. This key licensing agreement considerably strengthen and mature the company profile and open opportunities for partnerships and licensing discussions with Pharma groups.

 

 

Read the press release